CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 4,200 target
Drug / intervention
Palbociclib +14 moredrug
Likely dose
Not stated in record
Key inclusion· 9
  • ✓Age 12 years or older
  • ✓Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma, or B-cell non-Hodgkin lymphoma
  • ✓No longer benefiting from or no standard anti-cancer treatment available/indicated
  • ✓Measurable disease per RECIST v1.1, Lugano criteria, or IMWG criteria
Key exclusion· 3
  • ✕Disease not measurable or assessable by radiographic imaging or physical examination
  • ✕Primary brain tumors
  • ✕New, untreated, or progressive leptomeningeal metastases

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02693535
NCT02693535Phase 2RecruitingHigh Momentum
Long Recruiting
CompareCT.gov

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

American Society of Clinical Oncology·interventional·Posted Feb 26, 2016·Updated May 29, 2026

In Brief

A Phase 2 clinical trial evaluating Palbociclib, Sunitinib, and 13 other interventions for Lymphoma, Non-Hodgkin and 2 related conditions. Currently recruiting, targeting 4,200 participants across 181 sites in 2 countries.

Signals

Enrolling ahead of pace

Detailed Summary

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
CountriesPuerto Rico, United States
CollaboratorsAstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Pfizer, Taiho Oncology, Inc., Novartis, Merck Institute for Therapeutic Research, Boehringer Ingelheim, Seattle Genetics (now a wholly owned subsidiary of Pfizer)

Timeline

Phase 2Recruiting
20162017201820192020202120222023202420252026202720282029
First PostedFeb 26, 2016
Enrollment StartMar 14, 2016
Primary CompletionDec 31, 2027
Study CompletionDec 31, 2028
TodayJul 2, 2026
Enrollment to primary: 11.8 yearsPosted 10.3 years agoPrimary completion in 1.5 years

Interventions

Palbociclibdrug

drug

Sunitinibdrug

drug

Temsirolimusdrug

drug

Trastuzumab and Pertuzumabdrug

drug

Vemurafenib and Cobimetinibdrug

drug

Regorafenibdrug

drug

Olaparibdrug

drug

Nivolumab and Ipilimumabdrug

drug

Abemaciclibdrug

drug

Talazoparibdrug

drug

Atezolizumab and Talazoparibdrug

drug

Tucatinib plus Trastuzumab Subcutaneous (SC)drug

drug

Futibatinibdrug

drug

Dabrafenib plus Trametinibdrug

Drug

Fam-Trastuzumab Deruxtecan-Nxki (TDxD)drug

Drug